

GF/B45/EDP26 ***Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Russian Federation and Zimbabwe)***

Approved on 3 November 2021

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER21; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

Table 1: Secretariat's Recommendation on Funding from C19RM¹

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country / Multicountry	Grant name	Currency	C19RM 2020 carry-over amount ²	Previously approved C19RM 2021 award ³	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
Russian Federation	RUS-H-HAF	US\$	0	0	2,812,493	2,812,493	28.1%	2,812,493	0
Zimbabwe	ZWE-H-UNDP	US\$	7,229,605	0	27,247,383	125,122,689	25.0%	134,783,771	34,273,369
	ZWE-M-MOHCC	US\$	1,993,855	37,126,648	60,748,658				
	ZWE-T-MOHCC	US\$	437,622	0	0				

¹ The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

² Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

³ This includes Secretariat approved Fast-track and Full Funding awards, as well as awards previously approved by the Board.